R. Ansiaux et al. discovered that vandetanib, an inhibitor of VEGFR-dependent angiogenesis, effectively decreases the oxygen consumption rate of tumor cells, thereby enhancing tumor oxygenation and gradually improving the efficacy of radiotherapy [64]. The gene discussed is KDR; the disease is neoplasm.